Business Wire

IDC MarketScape Positions TreviPay as a Major Player in Worldwide Accounts Receivable Automation Applications for the Enterprise

4.12.2024 14:00:00 CET | Business Wire | Press release

Share

TreviPay, the most-trusted B2B payments and invoicing network, today announced it has been named a Major Player in the IDC MarketScape: Worldwide Accounts Receivable Automation Applications for the Enterprise 2024 Vendor Assessment1. TreviPay was one of the 14 vendors with a SaaS or cloud offering to be evaluated for their accounts receivable (A/R) strategy and capabilities.

The IDC MarketScape report highlighted a selection of TreviPay’s strengths including:

  • Robust APIs: “The TreviPay suite of APIs enables merchants to directly integrate invoicing into any ecommerce platform, point-of-sale environment, or order management platform. In addition, TreviPay enables a white-labeled solution that may be embedded within the checkout, giving buyers a line of sight into how much credit they have available in real time. Terms to buyer and settlement with client are both independently configurable, enabling guaranteed DSO.”
  • Expanding/Expansive Ecosystem: “The most recent investments include a strategic partnership with Mastercard to give suppliers the ability to extend trade credit financing and invoicing using Mastercard's commercial card payment capabilities. Also, TreviPay recently announced a strategic partnership with Allianz Trade that integrates Allianz Trade's credit insurance into TreviPay solution for enhanced risk management that enables funding capabilities.”

The evaluation assesses vendors in two primary categories: strategies and capabilities. The strategy criteria measure how well the vendor’s future strategy aligns with what customers will require over the next three to five years, and measures functionality roadmap, extensibility, scalability, customer experience and 3rd platform strategy. And the capabilities criteria assess agility, automation, extensibility, flexibility, functionality, portfolio benefits, 3rd platform usage, and visibility.

“Traditional accounts receivable processes are ripe for disruption. As we saw in our vendor assessment, this is dynamic market with a range of A/R solutions for the enterprise, but only a few, like TreviPay, that offer an integrated order-to-cash solution along with native financing options,” said Kevin Permenter, senior research director, Financial Applications at IDC.

This recognition follows TreviPay’s recent news to expand its automated order-to-cash offering and further enhance the buyer onboarding experience by reducing manual reviews and speeding up credit decisioning to near real-time. It also comes on the heels of the TreviPay Crossroads conference which brought together clients, partners and industry leaders from across the B2B payments ecosystem.

“We are thrilled to be recognized by IDC MarketScape as a Major Player in Accounts Receivable Automation Applications for the Enterprise report noting our deep payment management functionality, robust APIs and expansive ecosystem as key strengths,” said Brandon Spear, CEO of TreviPay. “As a first-time participant in this evaluation, it is particularly gratifying to see our distinctive capabilities and forward-looking strategies recognized in this assessment. With our focus on working with the largest global brands, we have seen the massive opportunity in automating core A/R processes, offering more payment choice to buyers and providing perfect DSO to financial teams.”

Download an excerpt of the vendor assessment.

1 IDC, IDC MarketScape: Worldwide Accounts Receivable Automation Applications for the Enterprise 2024 Vendor Assessment, #US51740924, December 2024

About TreviPay

At TreviPay, we believe loyalty begins at the payment. By understanding the diverse and unique requirements of B2B sellers, TreviPay’s global B2B payments and invoicing network enables enterprises to provide payments choice and convenience, open new markets and automate accounts receivables. With more than four decades of experience, TreviPay serves leaders looking to build loyalty while driving efficiency and embracing new digital channels, especially in industries with large distribution networks such as manufacturing, retail, and transportation. For more information, visit www.trevipay.com.

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204578799/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye